Bingham et al.
11. Macgregor AM, Boggs L: Drug distribution in obesity and
following bariatric surgery: a literature review. Obes Surg
1996; 6(1):17–27
12. Yska JP, van der Linde S, Tapper VV, et al: Influence of
bariatric surgery on the use and pharmacokinetics of some
major drug classes. Obes Surg 2013; 23(6):819–825
13. Black K, Shea C, Dursun S, Kutcher S: Selective serotonin
reuptake inhibitor discontinuation syndrome: proposed diag-
nostic criteria. J Psychiatry Neurosci 2000; 25(3):255–261
14. Parker G, Blennerhassett J: Withdrawal reactions associated
with venlafaxine. Aust N Z J Psychiatry 1998; 32(2):291–294
15. Schatzberg AF, Haddad P, Kaplan EM, et al: Serotonin
reuptake inhibitor discontinuation syndrome: a hypothet-
ical definition. Discontinuation consensus panel. J Clin
Psychiatry 1997; 58(7 Suppl):5–10
16. Kalarchian MA, Marcus MD, Levine MD, Soulakova JN,
Courcoulas AP, Wisinski MS: Relationship of psychiatric
disorders to 6-month outcomes after gastric bypass. Surg
Obes Relat Dis 2008; 4(4):544–549
Psychosomatics 55:6, November/December 2014
17. Tack J, Arts J, Caenepeel P, De Wulf D, Bisschops R:
Pathophysiology, diagnosis and management of postoperative
dumping syndrome. Nat Rev Gastroenterol Hepatol 2009; 6
(10):583–590
18. Ditto KE: SSRI discontinuation syndrome. Awareness
as an approach to prevention. Postgrad Med 2003; 114(2):
79–84
19. Malone M: Altered drug disposition in obesity and
after bariatric surgery. Nutr Clin Pract 2003; 18(2):131–
135
20. Spitzer RL, Kroenke K, Williams JB: Validation and utility
of a self-report version of PRIME-MD: the PHQ primary
care study. Primary Care Evaluation of Mental Disorders.
Patient Health Questionnaire. J Am Med Assoc 1999; 282
(18):1737–1744
21. Cassin S, Sockalingam S, Hawa R, et al: Psychometric
properties of the Patient Health Questionnaire (PHQ-9) as a
depression screening tool for bariatric surgery candidates.
Psychosomatics 2013; 54(4):352–358
www.psychosomaticsjournal.org 697